Join
Live feed
·
PRReleasevia Quantisnow
Brickell Biotech Inc. logo

Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune and Inflammatory Diseases from Carna Biosciences

ByQuantisnow·Wall Street's wire, on your screen.
BBI· Brickell Biotech Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BBI (Brickell Biotech Inc.) and more on Quantisnow.